Our partner journal

Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy. The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies.

Established in 1990, HGT provides a prestigious forum for publishing scientific and clinical research, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.

HGT is published 12 times per year, including sections on Methods (product testing and development) and Clinical Development (regulatory review, toxicology and commercial development). The journal also publishes a wide range of reviews, commentaries and editorials.

Human Gene Therapy is pleased to offer ESGCT members, affiliates, and meeting attendees a special  rate for Open Access (OA) article publication. This member benefit, in collaboration with Liebert OA, offers authors 25% discount on OA page charges and colour art fees. OA may be ordered immediately upon article acceptance at this substantial savings.Publishing OA will make your article available to everyone, worldwide, in perpetuity for significantly increased readers, citations, and downloads.  Additional benefits include fast-track publication, direct deposit of the article into PubMedCentral on your behalf, eliminating the 12-month embargo period, and a targeted email broadcast featuring your OA article.

As an ESGCT member or affiliate you have the opportunity to make an impact in the human gene and cell therapy community with OA publication in Human Gene Therapy, HGT Methods, or HGT Clinical Development.

Human Gene Therapy looks forward to receiving your impactful article contribution and we encourage members to recommend  Human Gene Therapy to their library or institution to facilitate collaboration with colleagues.

Please note that you will need active ESGCT membership to avail of this and other member benefits.

Latest Impact Factor: * 5.695

*2020 Journal Citation Reports (Clarivate, 2020)

CiteScore™:  7.7